ATP7B rs121908225: Understanding the p.His1069Gln Variant
The rs121908225 variant in the ATP7B gene, also known as p.His1069Gln, is a well-documented genetic alteration associated with Wilson disease. This condition is an autosomal recessive disorder characterized by the impaired transport of copper, leading to its toxic accumulation in the liver, brain, and other organs.
What each genotype means
Typical ATP7B genotype
This genotype represents the common, non-variant form of the ATP7B gene at this location. It does not carry the p.His1069Gln mutation associated with Wilson disease. This result does not rule out other genetic causes of copper metabolism disorders.
This is the most common genotype found in the general population across all ancestries.
Wilson disease carrier status
You carry one copy of the p.His1069Gln variant, also known as H1069Q. Because Wilson disease is an autosomal recessive condition, carrying a single copy typically does not cause the disease, though you may be a carrier. You should discuss this result with a genetic counselor or physician to understand implications for family planning.
Carried by approximately 0.4% of individuals in European and Mediterranean ancestries, though frequencies vary significantly by region.
Increased risk for Wilson disease
This genotype indicates you carry two copies of the p.His1069Gln variant. This variant is a well-documented pathogenic mutation in the ATP7B gene that impairs copper transport. Individuals with biallelic pathogenic variants are at high risk for developing Wilson disease, a condition requiring clinical monitoring and management by a specialist.
This genotype is rare in the general population and is primarily identified in individuals diagnosed with or being screened for Wilson disease.
What is the rs121908225 Variant?
The rs121908225 variant is a specific single-nucleotide polymorphism (SNP) located within the ATP7B gene. In scientific literature, this variant is frequently referred to as p.His1069Gln, indicating that at position 1069 of the resulting protein, the amino acid histidine is replaced by glutamine. This change is classified as a missense mutation, meaning the genetic code is altered in a way that results in the production of a protein with a different amino acid than the original sequence. Because the ATP7B gene provides instructions for creating a copper-transporting enzyme, this specific alteration can disrupt the enzyme's ability to function correctly. It is widely recognized in clinical genetics as one of the most common pathogenic variants identified in individuals diagnosed with Wilson disease, particularly across Central and Eastern European populations.
The Role of the ATP7B Gene
The ATP7B gene is essential for maintaining healthy copper levels in the human body. It encodes a protein known as copper-transporting ATPase 2, which acts like a molecular pump. This protein is primarily active in liver cells, where it helps move excess copper into the bile so it can be excreted from the body. When the ATP7B gene contains pathogenic variants, the resulting protein may be unstable, misfolded, or unable to transport copper effectively. As a result, copper is not properly excreted and instead builds up in the liver. Over time, this excess copper can spill over into the bloodstream and accumulate in other vital organs, such as the brain, kidneys, and corneas. This systemic accumulation is the underlying cause of the clinical symptoms associated with Wilson disease, which can range from liver dysfunction to neurological and psychiatric challenges.
Research and Clinical Evidence
Research into rs121908225 has established it as a primary contributor to the genetic landscape of Wilson disease. Numerous studies have identified this variant in both homozygous individuals (who carry two copies of the variant) and compound heterozygous individuals (who carry the variant alongside a different pathogenic mutation). While the association between this variant and Wilson disease is strong, researchers have noted that the clinical presentation of the disease can be highly variable, even among those with the same genotype. This phenomenon, known as variable penetrance, suggests that other genetic or environmental factors may influence how the disease manifests. Because of this complexity, clinicians often use a combination of genetic testing, biochemical markers, and clinical evaluation to confirm a diagnosis. The evidence for this variant's pathogenicity is well-supported by its frequent presence in clinical registries of patients with confirmed copper metabolism disorders.
Population Frequency
The frequency of the rs121908225 variant varies significantly across different global populations. It is most frequently observed in individuals of Central and Eastern European ancestry, where it is considered a major driver of Wilson disease cases. In some studies, it has been reported as the most prevalent variant in pediatric and adult cohorts within these regions. Conversely, its frequency is much lower in other ethnic groups. Understanding these population-specific frequencies is important for genetic screening programs, as it helps prioritize which variants to test for based on an individual's ancestral background. While the variant is relatively rare in the general population, its high prevalence within specific groups makes it a critical focus for diagnostic testing and carrier screening.
Navigating Genetic Information
If you have received information about your status regarding the rs121908225 variant, it is important to understand what this means in a clinical context. Wilson disease is an autosomal recessive condition, meaning that typically, an individual must inherit two copies of a pathogenic variant—one from each parent—to be at risk for the disease. Being a carrier (having only one copy) generally does not result in the symptoms of Wilson disease. However, genetic information should never be used to self-diagnose or make medical decisions. If you are concerned about your genetic status or family history, the most appropriate step is to consult with a qualified healthcare provider or a genetic counselor. They can interpret your results in the context of your overall health and provide guidance on whether further clinical testing or monitoring is necessary.
How common is this variant?
The rs121908225 variant has an approximate allele frequency of 0.004 in European and Mediterranean populations, though it is significantly more common in specific Central and Eastern European cohorts.
Frequently asked questions
What is Wilson disease?
Wilson disease is a rare, inherited disorder that prevents the body from properly removing excess copper. This leads to copper buildup in the liver, brain, and other organs, which can cause serious health issues if left untreated.
Does having the rs121908225 variant mean I have Wilson disease?
Not necessarily. Wilson disease is an autosomal recessive condition, meaning it usually requires two copies of a pathogenic variant to manifest. A single copy typically identifies you as a carrier, but you should discuss your specific results with a medical professional.
How is Wilson disease treated?
Wilson disease is managed through medical treatments that help remove excess copper from the body or prevent its absorption. Treatment must be managed by a specialist, such as a hepatologist or neurologist, and is lifelong.
Should I get tested for this variant?
Genetic testing is usually recommended if you have a family history of Wilson disease or if you are experiencing symptoms suggestive of copper metabolism issues. You should speak with your doctor or a genetic counselor to determine if testing is appropriate for you.
Sources & further reading
Educational information only, last refreshed 9/23/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121908225?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29